This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Mosapride is a prokinetic 5-HT4 receptor agonist used to stimulate gastric motility.
- Generic Name
- Mosapride
- DrugBank Accession Number
- DB11675
- Background
Mosapride is under investigation for the treatment and prevention of Postoperative Ileus and Gastric Peroral Endoscopic Pyloromyotomy (G-POEM). Mosapride has been investigated for the treatment and diagnostic of Constipation, Type 2 Diabetes, Functional Dyspepsia, Functional Constipation, and Epigastric Pain Syndrome, among others.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Mosapride (DB11675)
- Weight
- Average: 421.9
Monoisotopic: 421.1568475 - Chemical Formula
- C21H25ClFN3O3
- Synonyms
- Mosapride
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your software1,2-Benzodiazepine The risk or severity of CNS depression can be increased when Mosapride is combined with 1,2-Benzodiazepine. Acenocoumarol The risk or severity of adverse effects can be increased when Mosapride is combined with Acenocoumarol. Acetazolamide The risk or severity of CNS depression can be increased when Acetazolamide is combined with Mosapride. Acetophenazine The risk or severity of CNS depression can be increased when Acetophenazine is combined with Mosapride. Agomelatine The risk or severity of CNS depression can be increased when Agomelatine is combined with Mosapride. Alfentanil The risk or severity of CNS depression can be increased when Alfentanil is combined with Mosapride. Alimemazine The risk or severity of CNS depression can be increased when Alimemazine is combined with Mosapride. Almotriptan The risk or severity of CNS depression can be increased when Almotriptan is combined with Mosapride. Alosetron The risk or severity of CNS depression can be increased when Alosetron is combined with Mosapride. Alprazolam The risk or severity of CNS depression can be increased when Alprazolam is combined with Mosapride. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Mosapride Citrate MF497J489P 112885-42-4 HUZTYZBFZKRPFG-UHFFFAOYSA-N - International/Other Brands
- Gasmotin (Dainippon Pharmaceutical Co., Ltd.)
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image BONDIGEST COMPLEX® TABLETAS Mosapride Citrate (5 mg) + Pancrelipase (170 mg) + Simethicone (125 mg) Tablet, coated Oral 2008-10-01 Not applicable Colombia 
Categories
- ATC Codes
- A03FA09 — Mosapride
- Drug Categories
- Acids, Carbocyclic
- Alimentary Tract and Metabolism
- Amides
- Anti-Ulcer Agents
- Antidepressive Agents
- Benzene Derivatives
- Benzoates
- Central Nervous System Depressants
- Drugs for Functional Gastrointestinal Disorders
- Gastrointestinal Agents
- Neurotransmitter Agents
- Oxazines
- Propulsives
- Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
- Serotonin Agents
- Serotonin Receptor Agonists
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as aminophenyl ethers. These are aromatic compounds that contain a phenol ether, which carries an amine group on the benzene ring.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Phenol ethers
- Sub Class
- Aminophenyl ethers
- Direct Parent
- Aminophenyl ethers
- Alternative Parents
- Aniline and substituted anilines / Phenylmethylamines / Phenoxy compounds / Benzylamines / Alkyl aryl ethers / Aralkylamines / Chlorobenzenes / Fluorobenzenes / Aryl chlorides / Aryl fluorides show 12 more
- Substituents
- Alkyl aryl ether / Amine / Aminophenyl ether / Aniline or substituted anilines / Aralkylamine / Aromatic heteromonocyclic compound / Aryl chloride / Aryl fluoride / Aryl halide / Azacycle show 29 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- I8MFJ1C0BY
- CAS number
- 112885-41-3
- InChI Key
- YPELFRMCRYSPKZ-UHFFFAOYSA-N
- InChI
- InChI=1S/C21H25ClFN3O3/c1-2-28-20-10-19(24)18(22)9-17(20)21(27)25-11-16-13-26(7-8-29-16)12-14-3-5-15(23)6-4-14/h3-6,9-10,16H,2,7-8,11-13,24H2,1H3,(H,25,27)
- IUPAC Name
- 4-amino-5-chloro-2-ethoxy-N-({4-[(4-fluorophenyl)methyl]morpholin-2-yl}methyl)benzamide
- SMILES
- CCOC1=CC(N)=C(Cl)C=C1C(=O)NCC1CN(CC2=CC=C(F)C=C2)CCO1
References
- General References
- Allen Pharma: Digesal (mosapride citrate) oral tablets [Link]
- External Links
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Basic Science Type 2 Diabetes Mellitus 1 4 Completed Treatment Epigastric Pain Syndrome / Functional Dyspepsia / Postprandial Distress Syndrome 1 4 Unknown Status Other Colorectal Adenomas 1 4 Unknown Status Prevention Postoperative paralytic ileus 1 4 Unknown Status Treatment Chronic Constipation / Constipated Irritable Bowel Syndrome / Healthy Subjects (HS) 1 4 Unknown Status Treatment Diabetic Gastroparesis 1 4 Unknown Status Treatment Type 2 Diabetes Mellitus 1 3 Completed Diagnostic Foreign Body Left During Endoscopic Examination 1 3 Completed Prevention Prevention of Post Operative Ileus 1 3 Completed Treatment Constipation 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Suspension Oral 5 mg Tablet, coated Oral 10 mg Tablet, film coated Oral 5 mg Tablet, film coated Oral 5.28 mg Tablet, coated Oral Tablet Oral 5 mg Tablet, coated Oral 5 mg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0218 mg/mL ALOGPS logP 3.14 ALOGPS logP 2.75 Chemaxon logS -4.3 ALOGPS pKa (Strongest Acidic) 14.46 Chemaxon pKa (Strongest Basic) 5.98 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 76.82 Å2 Chemaxon Rotatable Bond Count 7 Chemaxon Refractivity 112.34 m3·mol-1 Chemaxon Polarizability 43.79 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available MS/MS Spectrum - , positive LC-MS/MS splash10-00dj-0910400000-7b60d0e3ee1a9a5d92c9
Drug created at October 20, 2016 20:38 / Updated at May 07, 2021 21:07